Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: Relapse and recapture rates, with predictive factors in 237 patients

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 11-12, 2014, Pages 1313-1323

  Kennedy, N A ^a   Kalla, R ^a   Warner, B ^b   Gambles, C J ^a   Musy, R ^a   Reynolds, S ^c   Dattani, R ^d   Nayee, H ^d   Felwick, R ^e   Harris, R ^e   Marriott, S ^f   Senanayake, S M ^g   Lamb, C A ^h   Al Hilou, H ⁱ   Gaya, D R ^j   Irving, P M ⁱ   Mansfield, J ^k   Parkes, M ^g   Ahmad, T ^f   Cummings, J R F ^e   Arnott, I D ^a   Satsangi, J ^a   Lobo, A J ^c   Smith, M ^b   Lindsay, J O ^d   Lees, C W ^a   more..

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d BARTS HEALTH NHS TRUST   (United Kingdom)

^e SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^f UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

^h NEWCASTLE UNIVERSITY   (United Kingdom)

ⁱ GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^j GLASGOW ROYAL INFIRMARY   (United Kingdom)

^k ROYAL VICTORIA INFIRMARY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; HEMOGLOBIN; MERCAPTOPURINE; TUMOR NECROSIS FACTOR ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COLON RESECTION; CROHN DISEASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RELAPSE; REMISSION; RETROSPECTIVE STUDY; TREATMENT DURATION; ULCERATIVE COLITIS; UNITED KINGDOM; CLINICAL TRIAL; COLITIS, ULCERATIVE; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; RISK FACTOR;

6-MERCAPTOPURINE; ADULT; AZATHIOPRINE; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84909638689     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12980     Document Type: Article

References (31)

1. Brooke BN, Hoffmann DC, Swarbrick ET. Azathioprine for Crohn's disease. Lancet 1969; 2: 612-4.
2. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn' s disease. Gut 1995; 37: 674-8.
3. O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 2: 955-7.
4. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-7.
5. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902.
6. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132-42.
7. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; 2: CD000067.
8. Timmer A, McDonald JWD, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 9: CD000478.
9. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9.
10. Chaparro M, Ordás I, Cabré E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis 2013; 19: 1404-10.
11. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-5.
12. Anstey A, Lennard L, Mayou SC, et al. Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med 1992; 85: 752-6.
13. Gisbert JP, González-Lama Y, Maté J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007; 102: 1518-27.
14. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
15. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621-8; e1-5.
16. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
17. Bouhnik Y, Lémann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-9.
18. Treton X, Bouhnik Y, Mary J-Y, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7: 80-5.
19. Lémann M, Mary J-Y, Colombel J-F, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812-8.
20. Kim PS, Zlatanic J, Korelitz BI, et al. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol 1999; 94: 3254-7.
21. Vilien M, Dahlerup JF, Munck LK, et al. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. Aliment Pharmacol Ther 2004; 19: 1147-52.
22. Lobel EZ, Korelitz BI, Xuereb MA, et al. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol 2004; 99: 462-5.
23. Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009; 104: 2760-7.
24. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-2.
25. French H, Mark Dalzell A, Srinivasan R, et al. Relapse rate following azathioprine withdrawal in maintaining remission for Crohn's disease: a meta-analysis. Dig Dis Sci 2011; 56: 1929-36.
26. Louis E, Mary J-Y, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70 e5; quiz e31.
27. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 30-5.
28. Matsumoto S, Miyatani H, Yoshida Y. Ulcerative colitis: comparison between elderly and young adult patients and between elderly patients with late-onset and long-standing disease. Dig Dis Sci 2013; 58: 1306-12.
29. Ha CY, Katz S. Clinical outcomes and management of inflammatory bowel disease in the older patient. Curr Gastroenterol Rep 2013; 15: 310.
30. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2218-24.
31. Sokol H, Seksik P, Nion-Larmurier I, et al. Current smoking, not duration of remission, delays Crohn's disease relapse following azathioprine withdrawal. Inflamm Bowel Dis 2010; 16: 362-3.